<DOC>
	<DOCNO>NCT00002396</DOCNO>
	<brief_summary>To evaluate safety single multiple dos ( 28 daily dos ) 9- [ 2- ( R ) - [ [ bi [ [ ( isopropoxycarbonyl ) - oxy ] methoxy ] phosphinoyl ] methoxy ] propyl ] adenine fumarate ( PMPA ) prodrug administer orally HIV-infected patient . To determine pharmacokinetics single multiple dos PMPA prodrug administer orally HIV-infected patient . To evaluate anti-HIV activity PMPA prodrug , demonstrate increase CD4 cell count decrease HIV RNA , administer orally single dose daily 4 week HIV-infected patient CD4 cell count 200 cells/mm3 .</brief_summary>
	<brief_title>The Safety Effectiveness PMPA Prodrug HIV-Infected Patients</brief_title>
	<detailed_description>In double-blind , placebo-controlled study , total 60 patient randomized receive PMPA prodrug 1 5 dos match placebo tablet . Part A ( Days 1-7 ) : Patients receive single dose PMPA prodrug match placebo tablet administer orally follow 1-week observation period . Patients complete Part A without dose-limiting toxicity begin Part B . Part B ( Days 8-35 ) : Patients receive either PMPA prodrug match placebo tablet administer orally qd 4 week dosage level administer Part A .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection , indicated seropositivity HIV infection ( ELISA Western blot ) , positive HIV culture , positive plasma HIV RNA . CD4 cell count 200 cells/mm3 within 28 day prior study entry . Plasma HIV RNA 10,000 copies/ml within 28 day study entry . Minimum life expectancy 12 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active , serious infection ( HIV infection ) require parenteral antibiotic therapy . Patients consider recover least 2 week elapse follow cessation parenteral antibiotic therapy enrollment . Active clinically significant medical problem include cardiac disease ( e.g. , symptoms ischemia , congestive heart failure , arrhythmia ) . Positive test Hepatitis B surface antigen ( HBsAg ) . Malignancy basal cell carcinoma cutaneous Kaposi 's sarcoma . Prior Medication : Excluded : Adefovir dipivoxil ( bisPOM PMEA ) 14 day . Within 2 week prior entry : Antiretroviral therapy , include nucleoside analogue , nonnucleoside reverse transcriptase inhibitor , protease inhibitor , investigational antiretroviral agent . Interferon ( alpha , beta , gamma ) interleukin ( e.g. , IL2 ) therapy , aminoglycoside antibiotic , amphotericin B , cidofovir , diuretic , foscarnet , ganciclovir , itraconazole , fluconazole , ketoconazole ( topical allow ) , isoniazid , rifampin , rifabutin , clarithromycin , azithromycin , systemic chemotherapeutic agent , systemic corticosteroid , agent significant nephrotoxic potential , agent may inhibit compete elimination via active renal tubular secretion ( e.g. , probenecid ) , investigational agent . Risk Behavior : Excluded : Active drug alcohol abuse demonstrate positive screen test drug abuse ( except marijuana drug use medical indication ) substance abuse consider sufficient hinder patient compliance . Patients receive : Antiretroviral therapy , include nucleoside analogue , nonnucleoside reverse transcriptase inhibitor , protease inhibitor , investigational antiretroviral agent . NOTE : Antiretroviral therapy may start completion Day 49 followup visit ( i.e. , early 14 day completion dose ) . Interferon ( alpha , beta , gamma ) interleukin ( e.g. , IL2 ) therapy , aminoglycoside antibiotic , amphotericin B , cidofovir , diuretic , foscarnet , ganciclovir , itraconazole , fluconazole , ketoconazole ( topical allow ) , isoniazid , rifampin , rifabutin , clarithromycin , azithromycin , systemic chemotherapeutic agent , systemic corticosteroid , agent significant nephrotoxic potential , agent significant nephrotoxic potential , agent may inhibit compete elimination via active renal tubular secretion ( e.g. , probenecid ) , investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Adenine</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>